Antikor Management / Research & Development

Dr Mahendra Deonarain, Chief Scientitic Officer, Co-Founder. See 'Board of Directors'.

Dr Gokhan Yahioglu, Director of Chemistry, Co-Founder. 

Dr Yahioglu has over 20 years’ experience  in the development of targeted therapies and diagnostics in oncology. Prior to Antikor, Dr Yahioglu was co-founder of PhotoBiotics an Imperial College spin-out where he led the chemistry and help develop the companies antibody targeting technology. He has held post-doctoral positions and both Cambridge University and Imperial College and is a highly cited medicinal chemist with over 60 peer-reviewed papers and granted patents.

Dr Till Medinger, Chairman of the Board. See 'Board of Directors'.

Dr Elizabeth Rollinson, Chairwoman of the Scientific Advisory Board, Advisor.

Dr Carlos Pittol, Business Development Manager & investor relations.

Dr Carlos Pittol is a Director of Clubb Capital Ltd, London, raising venture capital and providing BD assistance to start-up, early and mid-stage companies. He has over 15 years experience working as a financial analyst in the biotechnology and medical technology industries. Carlos is a chartered fellow of the Royal Society of Chemistry and of the Chartered Institute of Securities and Investments.

Research and Development Team (left to right)

Mahendra Deonarain (CSO), Ashleigh Stewart (Cell Biologist), Anja Pomowski (Senior Scientist, Antibody Engineering and Production), Gokhan Yahioglu (Director of Chemistry), Soraya Diez-Posada (Senior Scientist, Cell Biology), Bryan Edwards (Head of Antibody Discovery), Ioannna Stamati (Team Leader, Bioconjugation and Analyses), Eifion Robertson (Senior Scientist, Synthetic Chemistry)